Beyond Biotech - the podcast from Labiotech

Are mitochondrial therapeutics about to go mainstream?

Labiotech Episode 140
Audio Player
00:00
00:00 | 37:47

Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough?

Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. He joins 'Beyond Biotech' to talk cell mitophagy, biotech agility, and innovation in tackling neurodegenerative disease.

00:42    Introducing Klaus Dugi

02:51    Lessons learned in top pharma

05:10    The gap that Vandria seeks to fill

06:21    Mitochondrial therapeutics

07:45    Mitophagy inducers and how they work

14:53    Comparing approaches to treating neurodegenerative diseases

17:20    Aging, longevity, and healthy life years

25:26    Challenges ahead

27:31    Performance enhancement and resilience

31:15    Towards the mainstream?

34:35    Looking forward for Vandria

36:02    Developments to watch out for in mitochondrial therapeutics

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter